Tune Therapeutics
Tune Therapeutics is a clinical-stage biotechnology company developing epigenome-based therapies that modulate gene expression without altering DNA sequence. The company applies a modular epigenome editing platform to discover and develop therapeutics (including an LNP-delivered RNA epigenetic silencer for chronic hepatitis B), advances candidates through preclinical models into early clinical trials, and uses its platform for target discovery, cell therapy engineering, and regenerative indications. Headquarters are in Durham, NC and Seattle, WA.
Industries
Nr. of Employees
medium (51-250)
Tune Therapeutics
Patents
Compositions, systems, and methods for regulation of Hepatitis B virus through targeted gene repression
US-12398394-B2
View DetailsCompositions, systems, and methods for regulation of Hepatitis B virus through targeted gene repression
US-12325858-B1
View DetailsCompositions, systems, and methods for regulation of Hepatitis b virus through targeted gene repression
US-12325857-B2
View DetailsCompositions, systems, and methods for regulation of hepatitis B virus through targeted gene repression
US-12252692-B2
View DetailsCompositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
US-12221608-B2
View DetailsCompositions, systems, and methods for epigenetic regulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression
US-12098399-B2
View Details
Compositions, systems, and methods for regulation of Hepatitis B virus through targeted gene repression
US-12398394-B2
View DetailsCompositions, systems, and methods for regulation of Hepatitis B virus through targeted gene repression
US-12325858-B1
View DetailsCompositions, systems, and methods for regulation of Hepatitis b virus through targeted gene repression
US-12325857-B2
View DetailsCompositions, systems, and methods for regulation of hepatitis B virus through targeted gene repression
US-12252692-B2
View DetailsCompositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
US-12221608-B2
View DetailsCompositions, systems, and methods for epigenetic regulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression
US-12098399-B2
View DetailsProducts
TUNE-401
Investigational epigenetic silencer delivered via lipid nanoparticle-encapsulated RNA, designed to epigenetically repress both integrated viral DNA and covalently closed circular DNA (cccDNA) of hepatitis B virus by directing methylation-based silencing without cutting host DNA.
TUNE-401
Investigational epigenetic silencer delivered via lipid nanoparticle-encapsulated RNA, designed to epigenetically repress both integrated viral DNA and covalently closed circular DNA (cccDNA) of hepatitis B virus by directing methylation-based silencing without cutting host DNA.
Expertise Areas
- Epigenome editing
- Multiplex functional genomics and target discovery
- Preclinical translational development (in vitro and in vivo models)
- HBV therapeutic development using epigenetic silencing
Key Technologies
- Epigenome editing (configurable effector modules)
- Non-cutting sequence-specific DNA-binding domains (dead-Cas variants, ZFPs, TALEs)
- Multiplex and combinatorial targeting libraries
- Genome-scale functional screening (pooled and arrayed)
News & Updates
Received Certificate for Clinical Trial from the Hong Kong Department of Health to begin a Phase 1b trial for an investigational epigenetic silencer for chronic hepatitis B.
Completed financing to advance epigenome editing programs and clinical-stage HBV program.
Presentation of Phase 1b/2a proof-of-concept data demonstrating durable, dose-dependent antiviral activity and evidence of direct cccDNA biomarker silencing in patients treated with an LNP-delivered RNA epigenome editing therapy.
Preclinical results demonstrating strong repression of HBV RNA and antigen in primary human hepatocytes and humanized mouse models following transient delivery of epigenome editors.
Clinical data demonstrating direct cccDNA biomarker loss and durable repression of multiple HBV biomarkers in early-phase cohorts treated with an LNP-delivered epigenome editor.
Reported durable repression of a therapeutically relevant gene in non-human primates after transient delivery of an epi-editing construct, with sustained biomarker changes.
Received Certificate for Clinical Trial from the Hong Kong Department of Health to begin a Phase 1b trial for an investigational epigenetic silencer for chronic hepatitis B.
Completed financing to advance epigenome editing programs and clinical-stage HBV program.
Presentation of Phase 1b/2a proof-of-concept data demonstrating durable, dose-dependent antiviral activity and evidence of direct cccDNA biomarker silencing in patients treated with an LNP-delivered RNA epigenome editing therapy.
Preclinical results demonstrating strong repression of HBV RNA and antigen in primary human hepatocytes and humanized mouse models following transient delivery of epigenome editors.
Clinical data demonstrating direct cccDNA biomarker loss and durable repression of multiple HBV biomarkers in early-phase cohorts treated with an LNP-delivered epigenome editor.
Reported durable repression of a therapeutically relevant gene in non-human primates after transient delivery of an epi-editing construct, with sustained biomarker changes.